Genentech: Steven Magnuson | Senior Director and Senior Principal Scientist, Discovery Chemistry

Scientists / Our Scientists

"The challenges of drug discovery, the opportunity to work with amazing colleagues, and the rewards of helping patients – what a great job!"

Years at Genentech

Publications

I got my PhD in organic chemistry from the University of Alberta and after a postdoctoral fellowship at Columbia University, I started my industrial career at Bayer. In 2007, I got the opportunity to work in the Discovery Chemistry Department at Genentech and help build a lead identification group as the small molecule effort expanded here. I was attracted to the company’s focus on science and helping patients. Since that time I’ve been able to work on projects throughout the drug discovery process from inception to clinical testing in different therapeutic areas. Every project is unique and the daily challenges of finding that ideal molecule means no two days are ever the same.

Featured Publication

GNE-781, A Highly Advanced Potent and Selective Bromodomain Inhibitor of Cyclic Adenosine Monophosphate Response Element Binding Protein, Binding Protein (CBP).

J Med Chem. 2017 Nov 22;60(22):9162-9183. Epub 2017 Sep 21.

Romero FA, Murray J, Lai KW, Tsui V, Albrecht BK, An L, Beresini MH, de Leon Boenig G, Bronner SM, Chan EW, Chen KX, Chen Z, Choo EF, Clagg K, Clark K, Crawford TD, Cyr P, de Almeida Nagata D, Gascoigne KE, Grogan JL, Hatzivassiliou G, Huang W, Hunsaker TL, Kaufman S, Koenig SG, Li R, Li Y, Liang X, Liao J, Liu W, Ly J, Maher J, Masui C, Merchant M, Ran Y, Taylor AM, Wai J, Wang F, Wei X, Yu D, Zhu BY, Zhu X, Magnuson S.

View Abstract

Early in my time at Genentech, my focus was on lead identification finding promising chemical series for new biological targets. It’s a fast pace area with lots of different chemistry, assays, and biology where we worked on a number of different collaborations focused on new technologies and novel research areas. I’ve also had the opportunity to lead project teams in the lead optimization space for both immunology and oncology targets as well as leading a project in Early Development on its path through advanced safety testing towards Phase 1 testing in people. I’ve learned a great deal in each of these different areas working alongside great scientists.

Tetrahydrofuran-Based Transient Receptor Potential Ankyrin 1 (TRPA1) Antagonists: Ligand-Based Discovery, Activity in a Rodent Asthma Model, and Mechanism-of-Action via Cryogenic Electron Microscopy

Journal of Medicinal Chemistry,

Jack A. Terrett; Huifen Chen; Daniel Shore; Elisia Villemure; Larouche-Gauthier; Martin Déry; Francis Beaumier; Léa Constantineau-Forget; Chantal Grand-Maître; Luce Lépissier; Stéphane Ciblat; Claudio Sturino; Yong Chen; Baihua Hu; Aijun Lu; Yunli Wang; Andrew P. Cridland; Stuart I. Ward; David Hackos; Rebecca M. Reese; Shannon Shields; Jun Chen; Alessia Balestrini; Lorena Riol Blanco; Wyne P. Lee; John Liu; Eric Suto; Xiumin Wu; Juan Zhang; Justin Q. Ly; Hank La; Kevin Johnson; Matt Baumgardner; Kang-Jye Chou; Alexis Rohou; Lionel Rouge; Brian Safina; Steven Magnuson; Matthew Volgraf

A TRPA1 inhibitor suppresses neurogenic inflammation and airway contraction for asthma treatment

Journal of Experimental Medicine, ISSN: 15409538 00221007

Alessia Balestrini; Victory Joseph; Michelle Dourado; Rebecca M. Reese; Shannon Shields; Lionel Rouge; Daniel D. Bravo; Tania Chernov-Rogan; Cary Austin; Huifen Chen; Lan Wang; Elisia Villemure; Daniel Shore; Vishal Verma; Baihua Hu; Yong Chen; Laurie Leong; Chris Bjornson; Kathy Hotzel; Alvin Gogineni; Wyne P. Lee; Eric Suto; Xiumin Wu; John Liu; Juan Zhang; Vineela Gandham; Jianyong Wang; Jian Payandeh; Claudio Ciferri; Alberto Estevez; Chris Arthur; Jens Kortmann; Ryan L. Wong; Jose E. Heredia; Jonas Martin Doerr; Min Jung; Jason A. Vander Heiden; Meron Roose-Girma; Lucinda Tam; Kai Barck; Rick Carano; Han Ting Ding; Bobby Brillantes; Christine Tam; Xiaoying Yang; Simon S. Gao; Justin Q. Ly; Liling Liu; Liuxi Chen; Bianca Liederer; Joseph Lin; Steven Magnuson; Jun Chen; David Hackos; Justin Elstrott; Alexis Rohou; Brian Safina; Matthew Volgraf; Rebecca N. Bauer; Lorena Riol Blanco

Attention: This page may not render properly. The browser you are using, Internet Explorer 10, is no longer supported.

Genentech takes the health and safety of our patients, customers, employees and local communities very seriously, and we are actively responding to the global COVID-19 pandemic. For more, please visit our COVID-19 response page or call 1-877-436-3683.

Steven Magnuson

Senior Director and Senior Principal Scientist, Discovery Chemistry

Featured Publication

GNE-781, A Highly Advanced Potent and Selective Bromodomain Inhibitor of Cyclic Adenosine Monophosphate Response Element Binding Protein, Binding Protein (CBP).